A Study of GQ1010 in Subjects With Advanced Solid Tumors

Summary

This is an open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of GQ1010 and preliminary anti-tumor efficacy in advanced malignant solid tumor subjects

Timeline

Start

2024-05-23

Primary completion

2028-05-23

Completion

2028-12-31

Drugs

Indications